bio 0.7.0

data/test/data/refseq/nm_126355.entret

@@ -0,0 +1,64 @@
+LOCUS       NM_126355                615 bp    mRNA    linear   PLN 25-JAN-2005
+DEFINITION  Arabidopsis thaliana Toll-Interleukin-Resistance (TIR)
+            domain-containing protein (At2g03030) mRNA, complete cds.
+ACCESSION   NM_126355
+VERSION     NM_126355.1  GI:18395472
+KEYWORDS    .
+SOURCE      Arabidopsis thaliana (thale cress)
+  ORGANISM  Arabidopsis thaliana
+            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
+            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicotyledons;
+            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
+COMMENT     PROVISIONAL REFSEQ: This record has not yet been subject to final
+            NCBI review. This record is derived from an annotated genomic
+            sequence (NC_003071). The reference sequence was derived from
+            mrna.At2g03030.1.
+FEATURES             Location/Qualifiers
+     source          1..615
+                     /organism="Arabidopsis thaliana"
+                     /mol_type="mRNA"
+                     /db_xref="taxon:3702"
+                     /chromosome="2"
+                     /map="unknown"
+                     /clone="CHR2v01212004"
+                     /ecotype="Columbia"
+     gene            1..615
+                     /locus_tag="At2g03030"
+                     /note="synonym: T17M13.20; Toll-Interleukin-Resistance
+                     (TIR) domain-containing protein"
+                     /db_xref="GeneID:814832"
+     CDS             1..615
+                     /locus_tag="At2g03030"
+                     /note="domain signature TIR exists, suggestive of a
+                     disease resistance protein;
+                     go_function: defense/immunity protein activity [goid
+                     0003793];
+                     go_process: defense response signaling pathway,
+                     resistance-gene dependent [goid 0009870]"
+                     /codon_start=1
+                     /product="Toll-Interleukin-Resistance (TIR)
+                     domain-containing protein"
+                     /protein_id="NP_178403.1"
+                     /db_xref="GI:15227520"
+                     /db_xref="GeneID:814832"
+                     /translation="MTFFSPTQVFLNYRGEQLRRSFVSHLIDAFERNEINFFVDKYEQ
+                     RGKDLKNLFLRIQESKIALAIFSTRYTESSWCLDELVKIKKLADKKKLHVIPIFYKVK
+                     VEDVRKQTGEFGDNFWTLAKVSSGDQIKKWKEALECIPNKMGLSLGDKSSEADFIKEV
+                     VKAVQCVVATIGLEEEEENHFGKKKRKDCKCELPDLKKSRTKKL"
+     misc_feature    22..423
+                     /locus_tag="At2g03030"
+                     /note="TIR; Region: Toll - interleukin 1 - resistance"
+                     /db_xref="CDD:22729"
+ORIGIN
+       1  atgacattct tctctcccac tcaggtgttt ttgaactaca ggggagaaca actgcgtcgc
+      61  agcttcgtga gccacctcat tgatgccttt gaaaggaatg agatcaactt cttcgtagac
+     121  aaatacgaac agagaggcaa agacctcaaa aatctctttc ttaggatcca agagtcgaag
+     181  atcgcgcttg ccatcttctc aaccagatac acggagtcaa gctggtgttt ggatgagttg
+     241  gtgaagataa agaaacttgc tgataaaaaa aaactccatg tcattccaat tttctacaag
+     301  gtgaaggtag aagacgttcg aaaacagaca ggtgagtttg gtgacaactt ctggacgctg
+     361  gcaaaggttt caagtggtga tcagatcaag aaatggaaag aagccttgga atgtatcccc
+     421  aacaagatgg gtttgtcgtt gggagacaag agttctgaag cagatttcat caaggaagtt
+     481  gttaaggcgg ttcagtgtgt tgtagcaacg attggacttg aggaagaaga agagaatcat
+     541  tttgggaaaa agaagagaaa ggattgcaaa tgtgagcttc ctgatttgaa gaaaagcaga
+     601  accaaaaagt tgtga
+//

data/test/data/uniprot/p53_human.uniprot

@@ -0,0 +1,1456 @@
+ID   P53_HUMAN      STANDARD;      PRT;   393 AA.
+AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
+AC   Q16810; Q16811; Q16848; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8;
+AC   Q9NP68; Q9NPJ2; Q9NZD0; Q9UBI2; Q9UQ61;
+DT   13-AUG-1987 (Rel. 05, Created)
+DT   01-MAR-1989 (Rel. 10, Last sequence update)
+DT   13-SEP-2005 (Rel. 48, Last annotation update)
+DE   Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53)
+DE   (Antigen NY-CO-13).
+GN   Name=TP53; Synonyms=P53;
+OS   Homo sapiens (Human).
+OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
+OC   Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
+OC   Homo.
+OX   NCBI_TaxID=9606;
+RN   [1]
+RP   NUCLEOTIDE SEQUENCE.
+RX   MEDLINE=85230577; PubMed=4006916;
+RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
+RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
+RT   cells.";
+RL   EMBO J. 4:1251-1255(1985).
+RN   [2]
+RP   NUCLEOTIDE SEQUENCE.
+RX   MEDLINE=87064416; PubMed=2946935;
+RA   Lamb P., Crawford L.;
+RT   "Characterization of the human p53 gene.";
+RL   Mol. Cell. Biol. 6:1379-1385(1986).
+RN   [3]
+RP   NUCLEOTIDE SEQUENCE.
+RX   MEDLINE=85267676; PubMed=3894933;
+RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
+RT   "Molecular cloning and in vitro expression of a cDNA clone for human
+RT   cellular tumor antigen p53.";
+RL   Mol. Cell. Biol. 5:1601-1610(1985).
+RN   [4]
+RP   NUCLEOTIDE SEQUENCE.
+RX   MEDLINE=87089826; PubMed=3025664;
+RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
+RA   Rotter V.;
+RT   "Molecular basis for heterogeneity of the human p53 protein.";
+RL   Mol. Cell. Biol. 6:4650-4656(1986).
+RN   [5]
+RP   NUCLEOTIDE SEQUENCE.
+RX   MEDLINE=89108008; PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
+RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
+RA   Georgiev G.P.;
+RT   "A variation in the structure of the protein-coding region of the
+RT   human p53 gene.";
+RL   Gene 70:245-252(1988).
+RN   [6]
+RP   NUCLEOTIDE SEQUENCE OF 101-393.
+RX   MEDLINE=85126934; PubMed=6396087;
+RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
+RA   Benchimol S.;
+RT   "Isolation and characterization of a human p53 cDNA clone: expression
+RT   of the human p53 gene.";
+RL   EMBO J. 3:3257-3262(1984).
+RN   [7]
+RP   NUCLEOTIDE SEQUENCE, VARIANTS BURKITT'S LYMPHOMA, AND VARIANT ARG-72.
+RX   MEDLINE=92007731; PubMed=1915267;
+RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
+RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
+RL   EMBO J. 10:2879-2887(1991).
+RN   [8]
+RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
+RX   MEDLINE=93303270; PubMed=8316628;
+RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
+RA   Mirzayans R.;
+RT   "Isolation of two cell lines from a human malignant glioma specimen
+RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
+RL   Radiat. Res. 134:349-354(1993).
+RN   [9]
+RP   NUCLEOTIDE SEQUENCE, AND VARIANT ARG-72.
+RX   MEDLINE=21264809; PubMed=11058590; DOI=10.1074/jbc.M007140200;
+RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
+RA   Zevotek N.;
+RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
+RT   enhances tumor necrosis factor cytotoxicity.";
+RL   J. Biol. Chem. 276:3361-3370(2001).
+RN   [10]
+RP   NUCLEOTIDE SEQUENCE.
+RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
+RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
+RN   [11]
+RP   NUCLEOTIDE SEQUENCE.
+RA   Rozemuller E.H., Tilanus M.G.J.;
+RT   "P53 genomic sequence. Corrections and polymorphism.";
+RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
+RN   [12]
+RP   NUCLEOTIDE SEQUENCE, AND VARIANTS SER-47; ARG-72; LYS-339 AND ALA-366.
+RA   Livingston R.J., Rieder M.J., Chung M.-W., Ritchie T.K., Olson A.N.,
+RA   Nguyen C.P., Gildersleeve H., Cassidy C.M., Johnson E.J.,
+RA   Swanson J.E., McFarland I., Yool B., Park C., Nickerson D.A.;
+RT   "NIEHS-SNPs, environmental genome project, NIEHS ES15478, Department
+RT   of Genome Sciences, Seattle, WA (URL: http://egp.gs.washington.edu).";
+RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
+RN   [13]
+RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72 AND LYS-286.
+RX   PubMed=11023613;
+RA   Anderson C.W., Allalunis-Turner M.J.;
+RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
+RT   M059K has a cancer-associated mutation in exon 8.";
+RL   Radiat. Res. 154:473-476(2000).
+RN   [14]
+RP   NUCLEOTIDE SEQUENCE, AND VARIANTS ARG-72; HIS-273 AND SER-309.
+RA   Azuma K., Shichijo S., Itoh K.;
+RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
+RT   restricted CTL.";
+RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
+RN   [15]
+RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-72 AND
+RP   ALA-278.
+RC   TISSUE=Kidney;
+RX   MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
+RA   Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
+RA   Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
+RA   Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
+RA   Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
+RA   Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
+RA   Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
+RA   Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
+RA   Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
+RA   Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
+RA   Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
+RA   Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
+RA   Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
+RA   Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
+RA   Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
+RA   Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
+RA   Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
+RA   Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
+RT   "Generation and initial analysis of more than 15,000 full-length human
+RT   and mouse cDNA sequences.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
+RN   [16]
+RP   NUCLEOTIDE SEQUENCE OF 1-379, AND VARIANTS ARG-72 AND ASN-139.
+RC   TISSUE=Lung carcinoma;
+RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
+RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
+RA   Varga J.L.;
+RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
+RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
+RT   bombesin.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
+RN   [17]
+RP   NUCLEOTIDE SEQUENCE OF 126-185.
+RA   Pan X.L., Zhang A.H.;
+RT   "Study on the effect of tumor suppressor gene p53 in arsenism
+RT   patients.";
+RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
+RN   [18]
+RP   NUCLEOTIDE SEQUENCE OF 261-298.
+RC   TISSUE=Blood;
+RA   Nimri L.F., Owais W., Momani E.;
+RT   "Detection of P53 gene mutations and serum p53 antibodies associated
+RT   with cigarette smoking.";
+RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
+RN   [19]
+RP   NUCLEOTIDE SEQUENCE OF 262-306.
+RC   TISSUE=Ovarian adenocarcinoma;
+RA   Filippini G., Soldati G.;
+RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
+RN   [20]
+RP   NUCLEOTIDE SEQUENCE OF 225-260.
+RC   TISSUE=Glial cell, and Glial tumor;
+RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
+RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
+RT   "Mutation detection utilizing a novel PCR approach for amplification
+RT   of the p53 gene from microdissected tissue: application to archival
+RT   tumor samples.";
+RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
+RN   [21]
+RP   NUCLEOTIDE SEQUENCE OF 225-260.
+RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
+RA   Lipsky P.E.;
+RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
+RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
+RN   [22]
+RP   NUCLEOTIDE SEQUENCE OF 332-366.
+RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
+RT   "Allelic variant in intron 9 of TP53 gene.";
+RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
+RN   [23]
+RP   RNA-BINDING.
+RX   MEDLINE=91141509; PubMed=1705009;
+RA   Samad A., Carroll R.B.;
+RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
+RT   linkage.";
+RL   Mol. Cell. Biol. 11:1598-1606(1991).
+RN   [24]
+RP   ALTERNATIVE SPLICING.
+RX   MEDLINE=96197761; PubMed=8632903;
+RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
+RA   Gilbert D., Iggo R., Frebourg T.;
+RT   "The human tumour suppressor gene p53 is alternatively spliced in
+RT   normal cells.";
+RL   Oncogene 12:813-818(1996).
+RN   [25]
+RP   NUCLEAR LOCALIZATION SIGNAL.
+RX   MEDLINE=90191730; PubMed=2156209;
+RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
+RT   "The p53 nuclear localisation signal is structurally linked to a
+RT   p34cdc2 kinase motif.";
+RL   Oncogene 5:423-426(1990).
+RN   [26]
+RP   MINIMAL REPRESSION DOMAIN.
+RX   MEDLINE=21125692; PubMed=11007800; DOI=10.1074/jbc.M008231200;
+RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
+RT   "p53 amino acids 339-346 represent the minimal p53 repression
+RT   domain.";
+RL   J. Biol. Chem. 276:1510-1515(2001).
+RN   [27]
+RP   INTERACTION WITH ING4.
+RX   MEDLINE=22635239; PubMed=12750254;
+RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
+RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
+RA   Harris C.C.;
+RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
+RL   Cancer Res. 63:2373-2378(2003).
+RN   [28]
+RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
+RX   MEDLINE=90280456; PubMed=2141171;
+RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
+RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
+RN   [29]
+RP   DEPHOSPHORYLATION BY PP2A.
+RX   MEDLINE=91172186; PubMed=1848668;
+RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
+RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
+RT   by protein phosphatase 2A: inhibition by small-t antigen.";
+RL   Mol. Cell. Biol. 11:1996-2003(1991).
+RN   [30]
+RP   O-GLYCOSYLATION.
+RX   MEDLINE=96197773; PubMed=8632915;
+RA   Shaw P., Freeman J., Bovey R., Iggo R.;
+RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
+RT   glycosylation and charged residues at the carboxy-terminus.";
+RL   Oncogene 12:921-930(1996).
+RN   [31]
+RP   PHOSPHORYLATION BY PRPK.
+RX   MEDLINE=21570176; PubMed=11546806; DOI=10.1074/jbc.M105669200;
+RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
+RA   Shigemoto K., Hitsumoto Y., Nikawa J.-I., Enomoto Y.;
+RT   "Cloning and characterization of a p53-related protein kinase
+RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
+RT   tumor cell lines, and the testes.";
+RL   J. Biol. Chem. 276:44003-44011(2001).
+RN   [32]
+RP   PHOSPHORYLATION SITE THR-18.
+RX   MEDLINE=20406546; PubMed=10951572; DOI=10.1038/sj.onc.1203709;
+RA   Lopez-Borges S., Lazo P.A.;
+RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
+RT   18 within the mdm-2 binding site of the p53 tumour suppressor
+RT   protein.";
+RL   Oncogene 19:3656-3664(2000).
+RN   [33]
+RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
+RX   MEDLINE=21659718; PubMed=11706030; DOI=10.1074/jbc.M108535200;
+RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
+RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
+RT   death.";
+RL   J. Biol. Chem. 277:2951-2957(2002).
+RN   [34]
+RP   PHOSPHORYLATION SITE THR-55, MUTAGENESIS OF THR-55, AND INTERACTION
+RP   WITH TAF1.
+RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
+RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
+RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
+RT   for TAF1 in cell G1 progression.";
+RL   Mol. Cell 13:867-878(2004).
+RN   [35]
+RP   ACETYLATION SITE LYS-305.
+RX   MEDLINE=22726738; PubMed=12724314; DOI=10.1074/jbc.M212574200;
+RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
+RT   "Identification and characterization of a novel p300-mediated p53
+RT   acetylation site, lysine 305.";
+RL   J. Biol. Chem. 278:25568-25576(2003).
+RN   [36]
+RP   ACETYLATION SITES LYS-373 AND LYS-382.
+RX   MEDLINE=20123976; PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
+RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
+RT   "Post-translational modification of p53 protein in response to
+RT   ionizing radiation analyzed by mass spectrometry.";
+RL   J. Mol. Biol. 295:853-864(2000).
+RN   [37]
+RP   DEACETYLATION OF LYS-382 BY SIRT1.
+RX   MEDLINE=21526627; PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
+RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S.-I., Frye R.A.,
+RA   Pandita T.K., Guarente L., Weinberg R.A.;
+RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
+RL   Cell 107:149-159(2001).
+RN   [38]
+RP   INTERACTION WITH HIPK2.
+RX   MEDLINE=22191252; PubMed=11925430; DOI=10.1074/jbc.M200153200;
+RA   Kim E.-J., Park J.-S., Um S.-J.;
+RT   "Identification and characterization of HIPK2 interacting with p73 and
+RT   modulating functions of the p53 family in vivo.";
+RL   J. Biol. Chem. 277:32020-32028(2002).
+RN   [39]
+RP   INTERACTION WITH HIPK2, PHOSPHORYLATION SITE SER-46, AND MUTAGENESIS
+RP   OF SER-46 AND LYS-382.
+RX   MEDLINE=21638685; PubMed=11740489; DOI=10.1038/ncb715;
+RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
+RA   Will H., Schmitz M.L.;
+RT   "Regulation of p53 activity by its interaction with homeodomain-
+RT   interacting protein kinase-2.";
+RL   Nat. Cell Biol. 4:1-10(2002).
+RN   [40]
+RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION SITE SER-46.
+RX   MEDLINE=21638694; PubMed=11780126; DOI=10.1038/ncb714;
+RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
+RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
+RA   Fanciulli M., Appella E., Soddu S.;
+RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
+RT   and mediates apoptosis.";
+RL   Nat. Cell Biol. 4:11-19(2002).
+RN   [41]
+RP   INTERACTION WITH P53DINP1.
+RX   MEDLINE=22863074; PubMed=12851404; DOI=10.1074/jbc.M301979200;
+RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
+RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
+RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
+RT   partners in regulating p53 activity.";
+RL   J. Biol. Chem. 278:37722-37729(2003).
+RN   [42]
+RP   INTERACTION WITH HIPK1.
+RX   MEDLINE=22608637; PubMed=12702766; DOI=10.1073/pnas.0530308100;
+RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
+RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
+RA   Mak T.W., Thukral S.K.;
+RT   "Characterization of cells and gene-targeted mice deficient for the
+RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
+RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
+RN   [43]
+RP   INTERACTIONS WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
+RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
+RA   An W., Kim J., Roeder R.G.;
+RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
+RT   transcriptional activation by p53.";
+RL   Cell 117:735-748(2004).
+RN   [44]
+RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
+RX   MEDLINE=22825602; PubMed=12944468;
+RX   DOI=10.1128/MCB.23.18.6396-6405.2003;
+RA   O'Keefe K., Li H., Zhang Y.;
+RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
+RT   cytoplasmic degradation but not ubiquitination.";
+RL   Mol. Cell. Biol. 23:6396-6405(2003).
+RN   [45]
+RP   REVIEW ON ZINC-BINDING PROPERTIES.
+RX   MEDLINE=21438235; PubMed=11554448; DOI=10.1089/15230860152542961;
+RA   Hainaut P., Mann K.;
+RT   "Zinc binding and redox control of p53 structure and function.";
+RL   Antioxid. Redox Signal. 3:611-623(2001).
+RN   [46]
+RP   STRUCTURE BY NMR OF 319-360.
+RX   MEDLINE=94294808; PubMed=8023159;
+RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
+RA   Appella E., Gronenborn A.M.;
+RT   "High-resolution structure of the oligomerization domain of p53 by
+RT   multidimensional NMR.";
+RL   Science 265:386-391(1994).
+RN   [47]
+RP   STRUCTURE BY NMR OF 325-355.
+RX   MEDLINE=95292092; PubMed=7773777;
+RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
+RT   "Solution structure of the tetrameric minimum transforming domain of
+RT   p53.";
+RL   Nat. Struct. Biol. 1:877-890(1994).
+RN   [48]
+RP   STRUCTURE BY NMR OF 326-354.
+RX   MEDLINE=98026899; PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
+RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
+RA   Halazonetis T.D.;
+RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
+RT   structure of the p53 oligomerization domain.";
+RL   EMBO J. 16:6230-6236(1997).
+RN   [49]
+RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
+RX   MEDLINE=94294806; PubMed=8023157;
+RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
+RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
+RT   understanding tumorigenic mutations.";
+RL   Science 265:346-355(1994).
+RN   [50]
+RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
+RX   MEDLINE=95184011; PubMed=7878469;
+RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
+RT   "Crystal structure of the tetramerization domain of the p53 tumor
+RT   suppressor at 1.7 angstroms.";
+RL   Science 267:1498-1502(1995).
+RN   [51]
+RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
+RX   MEDLINE=97081050; PubMed=8875929; DOI=10.1126/science.274.5289.948;
+RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
+RA   Levine A.J., Pavletich N.P.;
+RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
+RT   transactivation domain.";
+RL   Science 274:948-953(1996).
+RN   [52]
+RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
+RX   MEDLINE=97035414; PubMed=8875926; DOI=10.1126/science.274.5289.1001;
+RA   Gorina S., Pavletich N.P.;
+RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
+RT   domains of 53BP2.";
+RL   Science 274:1001-1005(1996).
+RN   [53]
+RP   REVIEW.
+RX   MEDLINE=94090335; PubMed=8266092;
+RA   Harris C.C.;
+RT   "p53: at the crossroads of molecular carcinogenesis and risk
+RT   assessment.";
+RL   Science 262:1980-1981(1993).
+RN   [54]
+RP   REVIEW ON VARIANTS.
+RX   MEDLINE=91289156; PubMed=1905840;
+RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
+RT   "p53 mutations in human cancers.";
+RL   Science 253:49-53(1991).
+RN   [55]
+RP   REVIEW ON VARIANTS.
+RX   MEDLINE=96271983; PubMed=8829653;
+RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
+RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
+RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
+RT   "Database of mutations in the p53 and APC tumor suppressor genes
+RT   designed to facilitate molecular epidemiological analyses.";
+RL   Hum. Mutat. 7:202-213(1996).
+RN   [56]
+RP   VARIANT ARG-72.
+RX   MEDLINE=91153807; PubMed=1999338; DOI=10.1007/BF00201836;
+RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
+RT   "Characterization of a frequent polymorphism in the coding sequence of
+RT   the Tp53 gene in colonic cancer patients and a control population.";
+RL   Hum. Genet. 86:369-370(1991).
+RN   [57]
+RP   VARIANT LFS THR-133.
+RX   MEDLINE=92034774; PubMed=1933902;
+RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
+RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
+RT   family.";
+RL   Cancer Res. 51:6385-6387(1991).
+RN   [58]
+RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
+RX   MEDLINE=91057657; PubMed=1978757;
+RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
+RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
+RA   Friend S.H.;
+RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
+RT   sarcomas, and other neoplasms.";
+RL   Science 250:1233-1238(1990).
+RN   [59]
+RP   VARIANT LFS ASP-245.
+RX   MEDLINE=91080929; PubMed=2259385; DOI=10.1038/348747a0;
+RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
+RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
+RT   with Li-Fraumeni syndrome.";
+RL   Nature 348:747-749(1990).
+RN   [60]
+RP   VARIANT LFS LEU-272.
+RX   MEDLINE=92147883; PubMed=1737852;
+RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
+RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
+RA   Knutsen T., Minna J.D.;
+RT   "Hereditary and acquired p53 gene mutations in childhood acute
+RT   lymphoblastic leukemia.";
+RL   J. Clin. Invest. 89:640-647(1992).
+RN   [61]
+RP   VARIANTS LFS HIS-273 AND VAL-325.
+RX   MEDLINE=92228023; PubMed=1565144;
+RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
+RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
+RA   Strong L.C.;
+RT   "Germline mutations of the p53 tumor-suppressor gene in children and
+RT   young adults with second malignant neoplasms.";
+RL   N. Engl. J. Med. 326:1309-1315(1992).
+RN   [62]
+RP   VARIANTS BREAST TUMORS GLN-132; SER-249; LYS-280 AND LYS-285.
+RX   MEDLINE=90295284; PubMed=1694291;
+RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
+RT   "Genetic and immunochemical analysis of mutant p53 in human breast
+RT   cancer cell lines.";
+RL   Oncogene 5:893-899(1990).
+RN   [63]
+RP   VARIANTS COLON TUMORS PHE-241 AND HIS-273.
+RX   MEDLINE=91017544; PubMed=1699228;
+RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
+RA   Gannon J.V., Lane D.P.;
+RT   "p53 mutations in colorectal cancer.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
+RN   [64]
+RP   VARIANTS ESOPHAGUS TUMOR VAL-154; VAL-245; GLN-248; LEU-278 AND
+RP   SER-278.
+RX   MEDLINE=91088630; PubMed=2263646;
+RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
+RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
+RN   [65]
+RP   VARIANTS COLORECTAL CANCER MUTATIONS.
+RX   MEDLINE=91282784; PubMed=1647768;
+RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
+RA   Wakui A., Yamazaki T.;
+RT   "Mutations of the P53 gene, including an intronic point mutation, in
+RT   colorectal tumors.";
+RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
+RN   [66]
+RP   VARIANTS ESOPHAGUS TUMORS LEU-152; ALA-155; HIS-175; PHE-176 AND
+RP   HIS-273.
+RX   MEDLINE=91330175; PubMed=1868473;
+RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
+RA   Roth J.A.;
+RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
+RL   Cancer Res. 51:4495-4499(1991).
+RN   [67]
+RP   VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN CHINA.
+RX   MEDLINE=91187113; PubMed=1849234; DOI=10.1038/350427a0;
+RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
+RT   "Mutational hotspot in the p53 gene in human hepatocellular
+RT   carcinomas.";
+RL   Nature 350:427-428(1991).
+RN   [68]
+RP   VARIANTS HEPATOCELLULAR CARCINOMAS MUTATIONS IN SOUTH AFRICA.
+RX   MEDLINE=91187114; PubMed=1672732; DOI=10.1038/350429a0;
+RA   Bressac B., Kew M., Wands J., Ozturk M.;
+RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
+RT   from southern Africa.";
+RL   Nature 350:429-431(1991).
+RN   [69]
+RP   VARIANTS HNSCC PHE-176; PHE-242; CYS-245; LEU-248 AND HIS-273.
+RX   MEDLINE=93007999; PubMed=1394225;
+RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
+RA   Casey G.;
+RT   "Frequent p53 mutations in head and neck cancer.";
+RL   Cancer Res. 52:5997-6000(1992).
+RN   [70]
+RP   VARIANTS ANOGENITAL CARCINOMAS.
+RX   MEDLINE=93010989; PubMed=1327751;
+RA   Crook T., Vousden K.H.;
+RT   "Properties of p53 mutations detected in primary and secondary
+RT   cervical cancers suggest mechanisms of metastasis and involvement of
+RT   environmental carcinogens.";
+RL   EMBO J. 11:3935-3940(1992).
+RN   [71]
+RP   VARIANTS ORAL SQUAMOUS CELL CARCINOMA CYS-205; GLU-281 AND LYS-285.
+RX   MEDLINE=93093790; PubMed=1459726;
+RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
+RA   Yamamoto H., Tsuchida N.;
+RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
+RT   squamous-cell carcinoma.";
+RL   Int. J. Cancer 52:867-872(1992).
+RN   [72]
+RP   VARIANT PRO-HIS-PRO-178 INS.
+RX   MEDLINE=93265016; PubMed=1303181;
+RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
+RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
+RL   Hum. Mol. Genet. 1:207-208(1992).
+RN   [73]
+RP   VARIANTS BURKITT'S LYMPHOMAS.
+RX   MEDLINE=93064692; PubMed=1437144;
+RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
+RA   Appella E., May P.;
+RT   "p53 mutations in Raji cells: characterization and localization
+RT   relative to other Burkitt's lymphomas.";
+RL   Oncogene 7:2161-2167(1992).
+RN   [74]
+RP   VARIANT NASOPHARYNGEAL CARCINOMA THR-280.
+RX   MEDLINE=92335329; PubMed=1631151;
+RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y., Cao Y.,
+RA   Yao K.-T., Colburn N.H.;
+RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
+RT   carcinoma.";
+RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
+RN   [75]
+RP   VARIANTS HNSCC.
+RX   MEDLINE=93235942; PubMed=7682763;
+RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
+RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
+RT   lines.";
+RL   Am. J. Pathol. 142:1131-1139(1993).
+RN   [76]
+RP   VARIANTS HNSCC.
+RX   MEDLINE=94006220; PubMed=8402617;
+RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
+RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
+RT   "The incidence of p53 mutations increases with progression of head and
+RT   neck cancer.";
+RL   Cancer Res. 53:4477-4480(1993).
+RN   [77]
+RP   VARIANTS COLON TUMORS.
+RX   MEDLINE=93330562; PubMed=8336944;
+RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
+RT   "Efficient screening of p53 mutations by denaturing gradient gel
+RT   electrophoresis in colorectal tumors.";
+RL   Oncogene 8:2213-2220(1993).
+RN   [78]
+RP   CHARACTERIZATION OF VARIANT ALA-143.
+RX   MEDLINE=94283378; PubMed=8013454;
+RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
+RT   "A temperature-sensitive mutant of human p53.";
+RL   EMBO J. 13:2535-2544(1994).
+RN   [79]
+RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
+RX   MEDLINE=95193787; PubMed=7887414;
+RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
+RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
+RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
+RL   Am. J. Hum. Genet. 56:608-615(1995).
+RN   [80]
+RP   VARIANT LFS HIS-175.
+RX   MEDLINE=96423319; PubMed=8825920;
+RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
+RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
+RA   Evans D.G.R.;
+RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
+RT   175 mutation in TP53.";
+RL   J. Med. Genet. 32:942-945(1995).
+RN   [81]
+RP   VARIANTS ESOPHAGEAL ADENOCARCINOMA PHE-176; SER-245; TRP-248; TRP-282
+RP   AND GLN-286.
+RX   MEDLINE=96233927; PubMed=8829627;
+RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
+RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
+RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
+RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
+RL   Hum. Mutat. 7:109-113(1996).
+RN   [82]
+RP   VARIANTS COLORECTAL TUMORS.
+RX   MEDLINE=97255965; PubMed=9101296;
+RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7;
+RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
+RA   Zeuthen J.;
+RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
+RT   to genetic diagnosis of colorectal cancer.";
+RL   Hum. Mutat. 9:348-355(1997).
+RN   [83]
+RP   VARIANT COLORECTAL CARCINOMA ILE-157.
+RX   MEDLINE=98080146; PubMed=9419979; DOI=10.1038/sj.onc.1201668;
+RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
+RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
+RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
+RT   "Drastic genetic instability of tumors and normal tissues in Turcot
+RT   syndrome.";
+RL   Oncogene 15:2877-2881(1997).
+RN   [84]
+RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
+RP   AND SER-278.
+RX   MEDLINE=98111377; PubMed=9450901;
+RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
+RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
+RA   Raubenheimer E.J.;
+RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
+RT   black African population sample.";
+RL   Hum. Mutat. 11:39-44(1998).
+RN   [85]
+RP   VARIANT NONCLASSICAL LFS CYS-337.
+RX   MEDLINE=98112421; PubMed=9452042;
+RA   Luca J.W., Strong L.C., Hansen M.F.;
+RT   "A germline missense mutation R337C in exon 10 of the human p53
+RT   gene.";
+RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
+RN   [86]
+RP   VARIANT LFS ILE-292.
+RX   MEDLINE=99414637; PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
+RA   Gueran S., Tunca Y., Imirzalioglu N.;
+RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
+RT   a Li-Fraumeni syndrome family.";
+RL   Cancer Genet. Cytogenet. 113:145-151(1999).
+RN   [87]
+RP   INVOLVEMENT IN CHOROID PLEXUS PAPILLOMA.
+RX   MEDLINE=22079076; PubMed=12085209; DOI=10.1038/sj/bjc/6600269;
+RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
+RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
+RT   "Investigations on a clinically and functionally unusual and novel
+RT   germline p53 mutation.";
+RL   Br. J. Cancer 86:1592-1596(2002).
+CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
+CC       growth arrest or apoptosis depending on the physiological
+CC       circumstances and cell type. Involved in cell cycle regulation as
+CC       a trans-activator that acts to negatively regulate cell division
+CC       by controlling a set of genes required for this process. One of
+CC       the activated genes is an inhibitor of cyclin-dependent kinases.
+CC       Apoptosis induction seems to be mediated either by stimulation of
+CC       BAX and FAS antigen expression, or by repression of Bcl-2
+CC       expression.
+CC   -!- COFACTOR: Binds 1 zinc ion per subunit.
+CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
+CC       consisiting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
+CC       a homotetramer. Interacts with histone acetyltransferases EP300
+CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
+CC       promoters. In vitro, the interaction of TP53 with cancer-
+CC       associated/HPV (E6) viral proteins leads to ubiquitination and
+CC       degradation of TP53 giving a possible model for cell growth
+CC       regulation. This complex formation requires an additional factor,
+CC       E6-AP, which stably associates with TP53 in the presence of E6. C-
+CC       terminus interacts with TAF1, when TAF1 is part of the TFIID
+CC       complex. Interacts with ING4 and this interaction may be indirect.
+CC       Found in a complex with CABLES1 and TP73. Interacts with HIPK1,
+CC       HIPK2, and P53DINP1.
+CC   -!- INTERACTION:
+CC       Q8TDN4:CABLES1; NbExp=1; IntAct=EBI-366083, EBI-604615;
+CC       Q9ESJ1:Cables1 (xeno); NbExp=1; IntAct=EBI-366083, EBI-604411;
+CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-366083, EBI-81215;
+CC       P42858:HD; NbExp=2; IntAct=EBI-366083, EBI-466029;
+CC       P09429:HMGB1; NbExp=1; IntAct=EBI-366083, EBI-389432;
+CC       P56273:MDM2 (xeno); NbExp=1; IntAct=EBI-366083, EBI-541233;
+CC       Q00987:MDM2; NbExp=1; IntAct=EBI-366083, EBI-389668;
+CC       P06748:NPM1; NbExp=3; IntAct=EBI-366083, EBI-78579;
+CC       P06748-1:NPM1; NbExp=1; IntAct=EBI-366083, EBI-354150;
+CC       Q06609:RAD51; NbExp=1; IntAct=EBI-366083, EBI-297202;
+CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
+CC       P20226:TBP; NbExp=1; IntAct=EBI-366083, EBI-355371;
+CC       Q7Z6Z7:UREB1; NbExp=2; IntAct=EBI-366083, EBI-625934;
+CC   -!- SUBCELLULAR LOCATION: Cytoplasmic and nuclear.
+CC   -!- ALTERNATIVE PRODUCTS:
+CC       Event=Alternative splicing; Named isoforms=2;
+CC       Name=1;
+CC         IsoId=P04637-1; Sequence=Displayed;
+CC       Name=2; Synonyms=I9RET;
+CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
+CC         Note=Seems to be non-functional. Expressed in quiescent
+CC         lymphocytes;
+CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
+CC       repression domain.
+CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
+CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
+CC       impairs its ability to induce proapoptotic program and modulate
+CC       cell senescence.
+CC   -!- PTM: Phosphorylated. Phosphorylation on Ser residues mediates
+CC       transcriptional activation. Phosphorylated by HIPK1 (By
+CC       similarity). Phosphorylated on Thr-18 by VRK1, which may prevent
+CC       the interaction with MDM2. Phosphorylated on Thr-55 by TAF1, which
+CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by
+CC       HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required
+CC       for acetylation by CREBBP.
+CC   -!- PTM: Dephosphorylated by PP2A. SV40 small T antigen inhibits the
+CC       dephosphorylation by the AC form of PP2A.
+CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
+CC       in EB-1 cell line.
+CC   -!- DISEASE: TP53 is found in increased amounts in a wide variety of
+CC       transformed cells. TP53 is frequently mutated or inactivated in
+CC       about 60% of cancers.
+CC   -!- DISEASE: Defects in TP53 are involved in esophageal squamous cell
+CC       carcinoma (ESCC) [MIM:133239]. ESCC is a tumor of the esophagus.
+CC   -!- DISEASE: Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS)
+CC       [MIM:151623]. LFS is an autosomal dominant familial cancer
+CC       syndrome that in its classic form is defined by the existence of
+CC       both a proband with a sarcoma and two other first-degree relatives
+CC       with a cancer by age 45 years. In these families the affected
+CC       relatives develop a diverse set of malignancies at unusually early
+CC       ages. The spectrum of cancers in LFS includes breast carcinomas,
+CC       soft-tissue sarcomas, brain tumors, osteosarcoma, leukemia and
+CC       adreno-cortical carcinoma. Other possible component tumors of LFS
+CC       are melanoma, gonadal cell tumors and carcinomas of the lung,
+CC       pancreas and prostate.
+CC   -!- DISEASE: Defects in TP53 are found in Barrett metaplasia; also
+CC       known as Barrett esophagus. It is a condition in which the
+CC       normally stratified squamous epithelium of the lower esophagus is
+CC       replaced by a metaplastic columnar epithelium. The condition
+CC       develops as a complication in approximately 10% of patients with
+CC       chronic gastroesophageal reflux disease and predisposes to the
+CC       development of esophageal adenocarcinoma.
+CC   -!- DISEASE: Defects in TP53 are involved in head and neck squamous
+CC       cell carcinomas (HNSCC) [MIM:275355].
+CC   -!- DISEASE: Defects in TP53 are involved in oral squamous cell
+CC       carcinoma (OSCC). Cigarette smoke is a prime mutagenic agent in
+CC       cancer of the aerodigestive tract.
+CC   -!- DISEASE: Defects in TP53 are a cause of lung cancer [MIM:211980].
+CC   -!- DISEASE: Defects in TP53 are a cause of choroid plexus papilloma
+CC       [MIM:260500]. Choroid plexus papilloma is a slow-growing benign
+CC       tumor of the choroid plexus that often invades the leptomeninges.
+CC       In children it is usually in a lateral ventricle but in adults it
+CC       is more often in the fourth ventricle. Hydrocephalus is common,
+CC       either from obstruction or from tumor secretion of cerebrospinal
+CC       fluid. If it undergoes malignant transformation it is called a
+CC       choroid plexus carcinoma. Primary choroid plexus tumors are rare
+CC       and usually occur in early childhood.
+CC   -!- SIMILARITY: Belongs to the p53 family.
+CC   -!- DATABASE: NAME=IARC TP53 mutation database;
+CC       NOTE=IARC db of somatic p53 mutations;
+CC       WWW="http://www.iarc.fr/p53/".
+CC   -!- DATABASE: NAME=Tokyo p53;
+CC       NOTE=University of Tokyo db of p53 mutations;
+CC       WWW="http://p53.genome.ad.jp/".
+CC   -!- DATABASE: NAME=p53 web site at the Institut Curie;
+CC       WWW="http://p53.curie.fr/".
+CC   -!- DATABASE: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;
+CC       WWW="http://www.infobiogen.fr/services/chromcancer/Genes/P53ID88.html".
+CC   --------------------------------------------------------------------------
+CC   This Swiss-Prot entry is copyright. It is produced through a collaboration
+CC   between  the Swiss Institute of Bioinformatics  and the  EMBL outstation -
+CC   the European Bioinformatics Institute.  There are no  restrictions on  its
+CC   use as long as its content is in no way modified and this statement is not
+CC   removed.
+CC   --------------------------------------------------------------------------
+DR   EMBL; X02469; CAA26306.1; -; mRNA.
+DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
+DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
+DR   EMBL; K03199; AAA59989.1; -; mRNA.
+DR   EMBL; M14694; AAA61211.1; -; mRNA.
+DR   EMBL; M14695; AAA61212.1; -; mRNA.
+DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
+DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
+DR   EMBL; X01405; CAA25652.1; -; mRNA.
+DR   EMBL; X60011; CAA42626.1; -; mRNA.
+DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
+DR   EMBL; X60013; CAA42628.1; -; mRNA.
+DR   EMBL; X60014; CAA42629.1; -; mRNA.
+DR   EMBL; X60015; CAA42630.1; -; mRNA.
+DR   EMBL; X60016; CAA42631.1; -; mRNA.
+DR   EMBL; X60017; CAA42632.1; -; mRNA.
+DR   EMBL; X60018; CAA42633.1; -; mRNA.
+DR   EMBL; X60019; CAA42634.1; -; mRNA.
+DR   EMBL; X60020; CAA42635.1; -; mRNA.
+DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
+DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
+DR   EMBL; AF307851; AAG28785.1; -; mRNA.
+DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
+DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
+DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
+DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
+DR   EMBL; AB082923; BAC16799.1; -; mRNA.
+DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
+DR   EMBL; BC003596; AAH03596.1; -; mRNA.
+DR   EMBL; AY429684; AAR10356.1; -; mRNA.
+DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
+DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
+DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
+DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
+DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
+DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
+DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
+DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
+DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
+DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
+DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
+DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
+DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
+DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
+DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
+DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
+DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
+DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
+DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
+DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
+DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
+DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
+DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
+DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
+DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
+DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
+DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
+DR   PIR; A25224; DNHU53.
+DR   PDB; 1A1U; NMR; A/C=324-358.
+DR   PDB; 1AIE; X-ray; @=326-356.
+DR   PDB; 1C26; X-ray; A=325-356.
+DR   PDB; 1DT7; NMR; X/Y=367-388.
+DR   PDB; 1GZH; X-ray; A/C=-.
+DR   PDB; 1H26; X-ray; E=376-386.
+DR   PDB; 1HS5; NMR; A/B=324-357.
+DR   PDB; 1KZY; X-ray; A/B=95-289.
+DR   PDB; 1OLG; NMR; A/B/C/D=319-360.
+DR   PDB; 1OLH; NMR; A/B/C/D=319-360.
+DR   PDB; 1PES; NMR; A/B/C/D=325-355.
+DR   PDB; 1PET; NMR; A/B/C/D=325-355.
+DR   PDB; 1SAE; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAF; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAG; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAH; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAI; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAJ; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAK; NMR; A/B/C/D=319-360.
+DR   PDB; 1SAL; NMR; A/B/C/D=319-360.
+DR   PDB; 1TSR; X-ray; A/B/C=94-312.
+DR   PDB; 1TUP; X-ray; A/B/C=94-312.
+DR   PDB; 1UOL; X-ray; A/B=94-312.
+DR   PDB; 1YCQ; X-ray; B=13-29.
+DR   PDB; 1YCR; X-ray; B=15-29.
+DR   PDB; 1YCS; X-ray; A=94-292.
+DR   PDB; 2BIM; X-ray; A/B=94-312.
+DR   PDB; 2BIN; X-ray; A=94-312.
+DR   PDB; 2BIO; X-ray; A=94-312.
+DR   PDB; 2BIP; X-ray; A=94-312.
+DR   PDB; 2BIQ; X-ray; A=94-312.
+DR   PDB; 3SAK; NMR; A/B/C/D=319-360.
+DR   IntAct; P04637; -.
+DR   TRANSFAC; T00671; -.
+DR   SWISS-2DPAGE; P04637; HUMAN.
+DR   Ensembl; ENSG00000141510; Homo sapiens.
+DR   HGNC; HGNC:11998; TP53.
+DR   H-InvDB; HIX0013510; -.
+DR   Reactome; P04637; -.
+DR   MIM; 191170; -.
+DR   MIM; 133239; -.
+DR   MIM; 151623; -.
+DR   MIM; 275355; -.
+DR   MIM; 211980; -.
+DR   MIM; 260500; -.
+DR   GO; GO:0005739; C:mitochondrion; IDA.
+DR   GO; GO:0005730; C:nucleolus; IDA.
+DR   GO; GO:0005524; F:ATP binding; IDA.
+DR   GO; GO:0005507; F:copper ion binding; IDA.
+DR   GO; GO:0000739; F:DNA strand annealing activity; IDA.
+DR   GO; GO:0004518; F:nuclease activity; TAS.
+DR   GO; GO:0005515; F:protein binding; IPI.
+DR   GO; GO:0046982; F:protein heterodimerization activity; IPI.
+DR   GO; GO:0003700; F:transcription factor activity; IDA.
+DR   GO; GO:0008270; F:zinc ion binding; TAS.
+DR   GO; GO:0006915; P:apoptosis; IDA.
+DR   GO; GO:0006284; P:base-excision repair; TAS.
+DR   GO; GO:0008635; P:caspase activation via cytochrome c; IDA.
+DR   GO; GO:0007569; P:cell aging; IMP.
+DR   GO; GO:0007050; P:cell cycle arrest; TAS.
+DR   GO; GO:0000075; P:cell cycle checkpoint; TAS.
+DR   GO; GO:0030154; P:cell differentiation; TAS.
+DR   GO; GO:0008283; P:cell proliferation; TAS.
+DR   GO; GO:0008630; P:DNA damage response, signal transduction re...; TAS.
+DR   GO; GO:0006310; P:DNA recombination; TAS.
+DR   GO; GO:0008628; P:induction of apoptosis by hormones; TAS.
+DR   GO; GO:0030308; P:negative regulation of cell growth; IMP.
+DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS.
+DR   GO; GO:0006289; P:nucleotide-excision repair; IMP.
+DR   GO; GO:0051262; P:protein tetramerization; TAS.
+DR   GO; GO:0046902; P:regulation of mitochondrial membrane permea...; TAS.
+DR   GO; GO:0006355; P:regulation of transcription, DNA-dependent; IDA.
+DR   InterPro; IPR002117; P53.
+DR   InterPro; IPR011615; P53_DNA_bd.
+DR   InterPro; IPR012346; P53_RUNT_DNA_bd.
+DR   InterPro; IPR010991; p53_tetrameristn.
+DR   Pfam; PF00870; P53; 1.
+DR   Pfam; PF07710; P53_tetramer; 1.
+DR   PRINTS; PR00386; P53SUPPRESSR.
+DR   ProDom; PD002681; P53; 1.
+DR   PROSITE; PS00348; P53; 1.
+KW   3D-structure; Acetylation; Activator; Alternative splicing;
+KW   Anti-oncogene; Apoptosis; Cell cycle; Disease mutation; DNA-binding;
+KW   Glycoprotein; Li-Fraumeni syndrome; Metal-binding; Nuclear protein;
+KW   Phosphorylation; Polymorphism; Transcription;
+KW   Transcription regulation; Zinc.
+FT   DNA_BIND    102    292
+FT   REGION        1     83       Interaction with HRMT1L2.
+FT   REGION        1     44       Transcription activation (acidic).
+FT   REGION      100    370       Interaction with HIPK1 (By similarity).
+FT   REGION      116    292       Interaction with AXIN1 (By similarity).
+FT   REGION      241    248       Interacts with the 53BP2 SH3 domain.
+FT   REGION      300    393       Interaction with CARM1.
+FT   REGION      319    360       Interaction with HIPK2.
+FT   REGION      325    356       Oligomerization.
+FT   REGION      368    387       Basic (repression of DNA-binding).
+FT   MOTIF       305    321       Bipartite nuclear localization signal.
+FT   MOTIF       339    350       Nuclear export signal.
+FT   METAL       176    176       Zinc.
+FT   METAL       179    179       Zinc.
+FT   METAL       238    238       Zinc.
+FT   METAL       242    242       Zinc.
+FT   BINDING     392    392       5'-phospho-RNA (covalent).
+FT   MOD_RES      15     15       Phosphoserine (by PRPK).
+FT   MOD_RES      18     18       Phosphothreonine (by VRK1).
+FT   MOD_RES      46     46       Phosphoserine (by HIPK2).
+FT   MOD_RES      55     55       Phosphothreonine (by TAF1).
+FT   MOD_RES     305    305       N6-acetyllysine.
+FT   MOD_RES     315    315       Phosphoserine (by CDC2).
+FT   MOD_RES     373    373       N6-acetyllysine.
+FT   MOD_RES     382    382       N6-acetyllysine.
+FT   VARSPLIC    332    341       IRGRERFEMF -> DGTSFQKENC (in isoform 2).
+FT                                /FTId=VSP_006535.
+FT   VARSPLIC    342    393       Missing (in isoform 2).
+FT                                /FTId=VSP_006536.
+FT   VARIANT       7      7       D -> H (in a skin tumor).
+FT                                /FTId=VAR_005851.
+FT   VARIANT      35     35       L -> F (in a liver tumor).
+FT                                /FTId=VAR_005852.
+FT   VARIANT      43     43       L -> S (in a renal tumor).
+FT                                /FTId=VAR_005853.
+FT   VARIANT      47     47       P -> S (in dbSNP:1800371).
+FT                                /FTId=VAR_014632.
+FT   VARIANT      53     53       W -> C (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005854.
+FT   VARIANT      60     60       P -> S (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005855.
+FT   VARIANT      72     72       P -> R (in dbSNP:1042522).
+FT                                /FTId=VAR_005856.
+FT   VARIANT      79     79       A -> T (in clone P53-H-1).
+FT                                /FTId=VAR_005857.
+FT   VARIANT      87     87       P -> Q (in a brain tumor).
+FT                                /FTId=VAR_005858.
+FT   VARIANT      94     94       S -> T (in a colon tumor).
+FT                                /FTId=VAR_005859.
+FT   VARIANT     110    110       R -> C (in a liver and an uterus tumor).
+FT                                /FTId=VAR_005860.
+FT   VARIANT     110    110       R -> L (in a liver tumor).
+FT                                /FTId=VAR_005861.
+FT   VARIANT     110    110       R -> P (in a breast tumor).
+FT                                /FTId=VAR_005862.
+FT   VARIANT     113    113       F -> C (in a lung tumor).
+FT                                /FTId=VAR_005863.
+FT   VARIANT     125    125       T -> M (in a lung tumor).
+FT                                /FTId=VAR_005864.
+FT   VARIANT     126    126       Y -> D (in a colorectal tumor).
+FT                                /FTId=VAR_005865.
+FT   VARIANT     126    126       Y -> N (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005866.
+FT   VARIANT     127    127       S -> F (in a lung tumor).
+FT                                /FTId=VAR_005867.
+FT   VARIANT     128    128       P -> S (in a breast tumor).
+FT                                /FTId=VAR_005868.
+FT   VARIANT     129    129       A -> D (in a sarcoma).
+FT                                /FTId=VAR_005869.
+FT   VARIANT     130    130       L -> R (in a liver tumor).
+FT                                /FTId=VAR_005870.
+FT   VARIANT     131    131       N -> K (in a colon tumor).
+FT                                /FTId=VAR_005872.
+FT   VARIANT     131    131       N -> S (in a liver tumor).
+FT                                /FTId=VAR_005871.
+FT   VARIANT     132    132       K -> M (in a sarcoma).
+FT                                /FTId=VAR_005873.
+FT   VARIANT     132    132       K -> Q (in a breast tumor).
+FT                                /FTId=VAR_005874.
+FT   VARIANT     133    133       M -> T (in LFS).
+FT                                /FTId=VAR_005875.
+FT   VARIANT     135    135       C -> F (in a colon tumor).
+FT                                /FTId=VAR_005877.
+FT   VARIANT     135    135       C -> S (in a colon tumor).
+FT                                /FTId=VAR_005876.
+FT   VARIANT     136    136       Q -> E (in a breast tumor).
+FT                                /FTId=VAR_005878.
+FT   VARIANT     136    136       Q -> K (in a colon tumor).
+FT                                /FTId=VAR_005879.
+FT   VARIANT     137    137       L -> Q (in a liver tumor).
+FT                                /FTId=VAR_005880.
+FT   VARIANT     138    138       A -> P (in a lung tumor).
+FT                                /FTId=VAR_005881.
+FT   VARIANT     139    139       K -> N (in a breast, an ovary tumor, a
+FT                                leukemia and a lymphoma).
+FT                                /FTId=VAR_005882.
+FT   VARIANT     140    140       T -> Y (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005883.
+FT   VARIANT     141    141       C -> F (in a breast tumor).
+FT                                /FTId=VAR_005885.
+FT   VARIANT     141    141       C -> G (in an ovary tumor).
+FT                                /FTId=VAR_005884.
+FT   VARIANT     141    141       C -> Y (in many types of tumors).
+FT                                /FTId=VAR_005886.
+FT   VARIANT     143    143       V -> A (in a colon tumor; strong DNA
+FT                                binding ability at 32.5 degrees Celsius;
+FT                                strong reduction of transcriptional
+FT                                activity at 37.5 degrees Celsius).
+FT                                /FTId=VAR_005887.
+FT   VARIANT     144    144       Q -> P (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005888.
+FT   VARIANT     145    145       L -> P (in a brain tumor).
+FT                                /FTId=VAR_005889.
+FT   VARIANT     145    145       L -> Q (in an esophagus tumor).
+FT                                /FTId=VAR_005890.
+FT   VARIANT     147    147       V -> D (in an ovary tumor).
+FT                                /FTId=VAR_005891.
+FT   VARIANT     147    147       V -> G (in a prostate tumor).
+FT                                /FTId=VAR_005892.
+FT   VARIANT     149    149       S -> P (in a breast tumor).
+FT                                /FTId=VAR_005893.
+FT   VARIANT     151    151       P -> A (in a brain and a colon tumor).
+FT                                /FTId=VAR_005894.
+FT   VARIANT     151    151       P -> S (in many types of tumors).
+FT                                /FTId=VAR_005895.
+FT   VARIANT     151    151       P -> T (in a breast tumor).
+FT                                /FTId=VAR_005896.
+FT   VARIANT     152    152       P -> L (in an esophagus tumor).
+FT                                /FTId=VAR_005897.
+FT   VARIANT     152    152       P -> S (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005898.
+FT   VARIANT     153    153       P -> T (in a colon tumor).
+FT                                /FTId=VAR_005899.
+FT   VARIANT     154    154       G -> V (in esophagus tumor).
+FT                                /FTId=VAR_005900.
+FT   VARIANT     155    155       T -> A (in an esophagus tumor).
+FT                                /FTId=VAR_005901.
+FT   VARIANT     156    156       R -> P (in an osteosarcoma cell line).
+FT                                /FTId=VAR_005902.
+FT   VARIANT     157    157       V -> D (in a liver tumor).
+FT                                /FTId=VAR_005903.
+FT   VARIANT     157    157       V -> I (in colorectal carcinoma; from a
+FT                                patient with Turcot syndrome).
+FT                                /FTId=VAR_012977.
+FT   VARIANT     157    157       V -> S (in a S. African hepatocellular
+FT                                carcinoma).
+FT                                /FTId=VAR_005904.
+FT   VARIANT     158    158       R -> C (in a noninvasive head and neck
+FT                                tumor).
+FT                                /FTId=VAR_005905.
+FT   VARIANT     158    158       R -> G (in a brain and a lung tumor).
+FT                                /FTId=VAR_005906.
+FT   VARIANT     158    158       R -> H (in many types of tumors).
+FT                                /FTId=VAR_005907.
+FT   VARIANT     160    160       M -> I (in a lung and a skin tumor).
+FT                                /FTId=VAR_005908.
+FT   VARIANT     161    161       A -> S (in a brain tumor).
+FT                                /FTId=VAR_005909.
+FT   VARIANT     162    162       I -> S (in a brain tumor).
+FT                                /FTId=VAR_005910.
+FT   VARIANT     162    162       I -> V (in an ovary tumor).
+FT                                /FTId=VAR_005911.
+FT   VARIANT     163    163       Y -> H (in HNSCC).
+FT                                /FTId=VAR_005912.
+FT   VARIANT     164    164       K -> N (in a lung tumor).
+FT                                /FTId=VAR_005913.
+FT   VARIANT     164    164       K -> Q (in a breast tumor).
+FT                                /FTId=VAR_005914.
+FT   VARIANT     165    165       Q -> L (in a breast tumor).
+FT                                /FTId=VAR_005915.
+FT   VARIANT     165    165       Q -> R (in an ovary tumor).
+FT                                /FTId=VAR_005916.
+FT   VARIANT     166    166       S -> L (in a lung tumor).
+FT                                /FTId=VAR_005917.
+FT   VARIANT     168    168       H -> R (in a brain tumor).
+FT                                /FTId=VAR_005918.
+FT   VARIANT     169    169       M -> I (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005919.
+FT   VARIANT     169    169       M -> T (in a noninvasive head and neck
+FT                                tumor).
+FT                                /FTId=VAR_005920.
+FT   VARIANT     170    170       T -> M (in a colon tumor).
+FT                                /FTId=VAR_005921.
+FT   VARIANT     170    170       T -> S (in a colon tumor).
+FT                                /FTId=VAR_005922.
+FT   VARIANT     172    172       V -> A (in a prostate tumor).
+FT                                /FTId=VAR_005923.
+FT   VARIANT     173    173       V -> E (in a colon tumor).
+FT                                /FTId=VAR_005924.
+FT   VARIANT     173    173       V -> L (in a cervical carcinoma).
+FT                                /FTId=VAR_005925.
+FT   VARIANT     173    173       V -> M (in a colon tumor).
+FT                                /FTId=VAR_005926.
+FT   VARIANT     174    174       R -> H (in the cell line Detroit 562 of
+FT                                squamous cell carcinoma).
+FT                                /FTId=VAR_005927.
+FT   VARIANT     175    175       R -> C (in a colon and an uterus tumor).
+FT                                /FTId=VAR_005928.
+FT   VARIANT     175    175       R -> G (in a brain tumor).
+FT                                /FTId=VAR_005929.
+FT   VARIANT     175    175       R -> H (in LFS and colon/esophagus/
+FT                                gastric tumors).
+FT                                /FTId=VAR_005932.
+FT   VARIANT     175    175       R -> L (in a breast and a colon tumor).
+FT                                /FTId=VAR_005930.
+FT   VARIANT     175    175       R -> P (in a cervical carcinoma).
+FT                                /FTId=VAR_005931.
+FT   VARIANT     176    176       C -> F (in esophagus tumors and many
+FT                                types of tumors).
+FT                                /FTId=VAR_005933.
+FT   VARIANT     176    176       C -> W (in a lung tumor).
+FT                                /FTId=VAR_005934.
+FT   VARIANT     177    177       P -> L (in a skin tumor).
+FT                                /FTId=VAR_005935.
+FT   VARIANT     178    178       H -> HPHP (in a Burkitt's lymphoma).
+FT                                /FTId=VAR_005936.
+FT   VARIANT     181    181       R -> L (in a cervical carcinoma).
+FT                                /FTId=VAR_005937.
+FT   VARIANT     182    182       C -> S (in a stomach tumor).
+FT                                /FTId=VAR_005938.
+FT   VARIANT     184    184       D -> Y (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005939.
+FT   VARIANT     186    186       D -> Y (in a breast tumor).
+FT                                /FTId=VAR_005940.
+FT   VARIANT     187    187       G -> C (in a breast tumor).
+FT                                /FTId=VAR_005941.
+FT   VARIANT     187    187       G -> S (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005942.
+FT   VARIANT     189    189       A -> P (in an ovary tumor).
+FT                                /FTId=VAR_005943.
+FT   VARIANT     190    190       P -> L (in a colorectal tumor).
+FT                                /FTId=VAR_005944.
+FT   VARIANT     191    191       P -> T (in a colon tumor).
+FT                                /FTId=VAR_005945.
+FT   VARIANT     192    192       Q -> R (in a colon tumor).
+FT                                /FTId=VAR_005946.
+FT   VARIANT     193    193       H -> D (in an uterus tumor).
+FT                                /FTId=VAR_005947.
+FT   VARIANT     193    193       H -> R (in LFS).
+FT                                /FTId=VAR_005948.
+FT   VARIANT     194    194       L -> P (in a colon tumor).
+FT                                /FTId=VAR_005949.
+FT   VARIANT     194    194       L -> R (in the cell line HU 281 of
+FT                                squamous cell carcinoma).
+FT                                /FTId=VAR_005950.
+FT   VARIANT     195    195       I -> T (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005951.
+FT   VARIANT     198    198       E -> K (in HNSCC).
+FT                                /FTId=VAR_005952.
+FT   VARIANT     205    205       Y -> C (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005953.
+FT   VARIANT     205    205       Y -> D (in HNSCC).
+FT                                /FTId=VAR_005954.
+FT   VARIANT     213    213       R -> Q (in a Burkitt's lymphoma and a
+FT                                colorectal tumor).
+FT                                /FTId=VAR_005955.
+FT   VARIANT     216    216       V -> M (in HNSCC).
+FT                                /FTId=VAR_005956.
+FT   VARIANT     220    220       Y -> C (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005957.
+FT   VARIANT     220    220       Y -> H (in a colon tumor).
+FT                                /FTId=VAR_005958.
+FT   VARIANT     220    220       Y -> S (in HNSCC).
+FT                                /FTId=VAR_005959.
+FT   VARIANT     228    228       D -> E (in HNSCC).
+FT                                /FTId=VAR_005960.
+FT   VARIANT     230    230       T -> I (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_005961.
+FT   VARIANT     232    232       I -> T (in an anal tumor).
+FT                                /FTId=VAR_005962.
+FT   VARIANT     234    234       Y -> C (in HNSCC).
+FT                                /FTId=VAR_005963.
+FT   VARIANT     234    234       Y -> H (in a Burkitt's lymphoma).
+FT                                /FTId=VAR_005964.
+FT   VARIANT     237    237       M -> I (in a colon tumor).
+FT                                /FTId=VAR_005965.
+FT   VARIANT     238    238       C -> F (in an anal tumor).
+FT                                /FTId=VAR_005966.
+FT   VARIANT     238    238       C -> Y (in a colorectal tumor).
+FT                                /FTId=VAR_005967.
+FT   VARIANT     240    240       S -> I (in an anal tumor).
+FT                                /FTId=VAR_005968.
+FT   VARIANT     241    241       S -> F (in a colon tumor).
+FT                                /FTId=VAR_005969.
+FT   VARIANT     242    242       C -> F (in a skin tumor).
+FT                                /FTId=VAR_005970.
+FT   VARIANT     245    245       G -> A (in a renal tumor).
+FT                                /FTId=VAR_005971.
+FT   VARIANT     245    245       G -> C (in LFS, colon and larynx tumors).
+FT                                /FTId=VAR_005972.
+FT   VARIANT     245    245       G -> D (in LFS and a colon tumor).
+FT                                /FTId=VAR_005973.
+FT   VARIANT     245    245       G -> S (in esophageal adenocarcinoma and
+FT                                many types of tumors).
+FT                                /FTId=VAR_005974.
+FT   VARIANT     245    245       G -> V (in HNSCC).
+FT                                /FTId=VAR_005975.
+FT   VARIANT     246    246       M -> R (in a liver tumor).
+FT                                /FTId=VAR_005976.
+FT   VARIANT     246    246       M -> T (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_005977.
+FT   VARIANT     246    246       M -> V (in many types of tumors).
+FT                                /FTId=VAR_005978.
+FT   VARIANT     247    247       N -> I (in a lung tumor).
+FT                                /FTId=VAR_005980.
+FT   VARIANT     247    247       N -> W (in a skin tumor).
+FT                                /FTId=VAR_005979.
+FT   VARIANT     248    248       R -> G (in an endocrine tumor).
+FT                                /FTId=VAR_005981.
+FT   VARIANT     248    248       R -> L (in tumors of hypopharynx, larynx
+FT                                and tonsil).
+FT                                /FTId=VAR_005982.
+FT   VARIANT     248    248       R -> Q (in LFS and many types of tumors).
+FT                                /FTId=VAR_005983.
+FT   VARIANT     248    248       R -> W (in LFS, esophageal adenocarcinoma
+FT                                and many types of tumors).
+FT                                /FTId=VAR_005984.
+FT   VARIANT     249    249       R -> G (in a breast tumor).
+FT                                /FTId=VAR_005985.
+FT   VARIANT     249    249       R -> S (in many types of tumors).
+FT                                /FTId=VAR_005986.
+FT   VARIANT     251    251       I -> N (in HNSCC).
+FT                                /FTId=VAR_005987.
+FT   VARIANT     252    252       L -> P (in LFS and many types of tumors).
+FT                                /FTId=VAR_005988.
+FT   VARIANT     254    254       I -> N (in a breast tumor).
+FT                                /FTId=VAR_017908.
+FT   VARIANT     254    254       I -> T (in a colon tumor).
+FT                                /FTId=VAR_017909.
+FT   VARIANT     257    257       L -> P (in HNSCC).
+FT                                /FTId=VAR_005989.
+FT   VARIANT     258    258       E -> D (in a colorectal tumor).
+FT                                /FTId=VAR_005990.
+FT   VARIANT     258    258       E -> K (in LFS).
+FT                                /FTId=VAR_005991.
+FT   VARIANT     272    272       V -> L (in LFS).
+FT                                /FTId=VAR_005992.
+FT   VARIANT     273    273       R -> C (in LFS, colorectal tumor and oral
+FT                                squamous cell carcinoma).
+FT                                /FTId=VAR_005993.
+FT   VARIANT     273    273       R -> G (in HNSCC).
+FT                                /FTId=VAR_005994.
+FT   VARIANT     273    273       R -> H (in LFS, colon and esophagus
+FT                                tumors).
+FT                                /FTId=VAR_005995.
+FT   VARIANT     274    274       V -> F (in a colorectal tumor).
+FT                                /FTId=VAR_005997.
+FT   VARIANT     275    275       C -> W (in a breast and a stomach tumor).
+FT                                /FTId=VAR_005999.
+FT   VARIANT     275    275       C -> Y (in LFS and tumors of brain, lung,
+FT                                kidney, stomach).
+FT                                /FTId=VAR_005998.
+FT   VARIANT     277    277       C -> G (in a lung tumor).
+FT                                /FTId=VAR_006000.
+FT   VARIANT     278    278       P -> A (in a breast tumor).
+FT                                /FTId=VAR_006001.
+FT   VARIANT     278    278       P -> H (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_006002.
+FT   VARIANT     278    278       P -> L (in an esophagus and a lung
+FT                                tumor).
+FT                                /FTId=VAR_006003.
+FT   VARIANT     278    278       P -> S (in oral squamous cell carcinoma).
+FT                                /FTId=VAR_006004.
+FT   VARIANT     278    278       P -> T (in HNSCC; same patient as
+FT                                mutation His-281).
+FT                                /FTId=VAR_006005.
+FT   VARIANT     279    279       G -> E (in a colorectal tumor).
+FT                                /FTId=VAR_006006.
+FT   VARIANT     280    280       R -> I (in a colorectal tumor).
+FT                                /FTId=VAR_006008.
+FT   VARIANT     280    280       R -> K (in a breast tumor).
+FT                                /FTId=VAR_006007.
+FT   VARIANT     280    280       R -> T (in nasopharyngeal carcinoma).
+FT                                /FTId=VAR_006009.
+FT   VARIANT     281    281       D -> A (in a leukemia and a lymphoma).
+FT                                /FTId=VAR_006010.
+FT   VARIANT     281    281       D -> E (in many types of tumors).
+FT                                /FTId=VAR_006011.
+FT   VARIANT     281    281       D -> G (in many types of tumors).
+FT                                /FTId=VAR_006012.
+FT   VARIANT     281    281       D -> H (in HNSCC; same patient as
+FT                                mutation Thr-278).
+FT                                /FTId=VAR_006013.
+FT   VARIANT     281    281       D -> V (in a colorectal tumor).
+FT                                /FTId=VAR_006014.
+FT   VARIANT     282    282       R -> L (in a breast tumor).
+FT                                /FTId=VAR_006015.
+FT   VARIANT     282    282       R -> W (in esophageal adenocarcinoma and
+FT                                many types of tumors).
+FT                                /FTId=VAR_006016.
+FT   VARIANT     283    283       R -> C (in a colon tumor).
+FT                                /FTId=VAR_006017.
+FT   VARIANT     283    283       R -> G (in a lung tumor).
+FT                                /FTId=VAR_006018.
+FT   VARIANT     283    283       R -> H (in a colon tumor).
+FT                                /FTId=VAR_006019.
+FT   VARIANT     283    283       R -> P (in a breast and a lung tumor).
+FT                                /FTId=VAR_006020.
+FT   VARIANT     284    284       T -> A (in a colorectal tumor).
+FT                                /FTId=VAR_006021.
+FT   VARIANT     284    284       T -> P (in a lung tumor).
+FT                                /FTId=VAR_006022.
+FT   VARIANT     285    285       E -> K (in many types of tumors).
+FT                                /FTId=VAR_006023.
+FT   VARIANT     285    285       E -> Q (in an uterus tumor).
+FT                                /FTId=VAR_006024.
+FT   VARIANT     285    285       E -> V (in a liver tumor).
+FT                                /FTId=VAR_006025.
+FT   VARIANT     286    286       E -> A (in LFS).
+FT                                /FTId=VAR_006026.
+FT   VARIANT     286    286       E -> D (in a liver tumor).
+FT                                /FTId=VAR_006027.
+FT   VARIANT     286    286       E -> G (in tumors of colon, lung, head
+FT                                and neck).
+FT                                /FTId=VAR_006028.
+FT   VARIANT     286    286       E -> K (in many types of tumors).
+FT                                /FTId=VAR_006029.
+FT   VARIANT     286    286       E -> Q (in esophageal adenocarcinoma).
+FT                                /FTId=VAR_006030.
+FT   VARIANT     292    292       K -> I (in LFS).
+FT                                /FTId=VAR_015819.
+FT   VARIANT     296    296       H -> P (in HNSCC).
+FT                                /FTId=VAR_006031.
+FT   VARIANT     300    300       P -> R (in a skin tumor).
+FT                                /FTId=VAR_006032.
+FT   VARIANT     301    301       P -> L (in a colon tumor).
+FT                                /FTId=VAR_006033.
+FT   VARIANT     302    302       G -> E (in a colon tumor).
+FT                                /FTId=VAR_006034.
+FT   VARIANT     302    302       G -> V (in a colon tumor).
+FT                                /FTId=VAR_006035.
+FT   VARIANT     306    306       R -> Q (in a sarcoma).
+FT                                /FTId=VAR_006036.
+FT   VARIANT     307    307       A -> T (in a breast tumor).
+FT                                /FTId=VAR_006037.
+FT   VARIANT     309    309       P -> S (in a colon tumor).
+FT                                /FTId=VAR_006038.
+FT   VARIANT     325    325       G -> V (in LFS).
+FT                                /FTId=VAR_006039.
+FT   VARIANT     334    334       G -> V (in a lung tumor).
+FT                                /FTId=VAR_006040.
+FT   VARIANT     337    337       R -> C (in LFS; nonclassical form; also
+FT                                found in a liver tumor).
+FT                                /FTId=VAR_006041.
+FT   VARIANT     339    339       E -> K.
+FT                                /FTId=VAR_022316.
+FT   VARIANT     366    366       S -> A.
+FT                                /FTId=VAR_022317.
+FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by HIPK2
+FT                                and acetylation of K-382 by CREBBP.
+FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
+FT   MUTAGEN     135    135       C->Y: Decreased E6-mediated binding to
+FT                                E6-AP.
+FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
+FT   CONFLICT     76     76       A -> G (in Ref. 2; AAA59987).
+FT   CONFLICT    155    155       T -> P (in Ref. 16).
+FT   CONFLICT    254    254       I -> D (in Ref. 7; CAA42635).
+FT   CONFLICT    262    262       G -> V (in Ref. 19).
+FT   CONFLICT    282    282       R -> Q (in Ref. 18).
+FT   STRAND      103    103
+FT   HELIX       105    107
+FT   TURN        108    108
+FT   STRAND      110    112
+FT   TURN        120    121
+FT   STRAND      124    127
+FT   TURN        128    131
+FT   STRAND      132    135
+FT   TURN        137    138
+FT   STRAND      141    146
+FT   TURN        153    154
+FT   STRAND      156    163
+FT   TURN        166    170
+FT   HELIX       177    181
+FT   TURN        191    192
+FT   STRAND      195    197
+FT   TURN        201    202
+FT   STRAND      204    207
+FT   TURN        209    211
+FT   STRAND      214    219
+FT   TURN        225    226
+FT   STRAND      230    236
+FT   TURN        240    241
+FT   TURN        243    248
+FT   STRAND      251    258
+FT   TURN        260    261
+FT   STRAND      264    274
+FT   HELIX       278    286
+FT   HELIX       335    354
+FT   HELIX       376    378
+FT   HELIX       379    384
+FT   TURN        385    386
+SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
+     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
+     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
+     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
+     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
+     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
+     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
+     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
+//